Organovo Holdings Inc (ONVO) Rating Lowered to Hold at Zacks Investment Research
Organovo Holdings Inc (NASDAQ:ONVO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday.
According to Zacks, “Organovo Holdings, Inc. is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. Its NovoGen 3D printing technology is a platform that works across various tissue and cell types. Organovo Holdings, Inc. is based in San Diego, California. “
Separately, Jefferies Group restated a “buy” rating and issued a $4.50 price objective (up from $4.00) on shares of Organovo Holdings in a research note on Thursday, July 21st.
Shares of Organovo Holdings (NASDAQ:ONVO) opened at 3.97 on Thursday. Organovo Holdings has a 52 week low of $1.60 and a 52 week high of $4.99. The firm’s 50-day moving average price is $3.95 and its 200 day moving average price is $3.37.
Organovo Holdings (NASDAQ:ONVO) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. Organovo Holdings had a negative return on equity of 59.27% and a negative net margin of 1,878.68%. On average, analysts predict that Organovo Holdings will post ($0.42) earnings per share for the current fiscal year.
In other news, EVP Eric David sold 20,000 shares of the company’s stock in a transaction on Friday, August 5th. The stock was sold at an average price of $4.55, for a total value of $91,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 12.50% of the stock is owned by insiders.
Several large investors have recently bought and sold shares of the company. Cowen Group Inc. raised its stake in Organovo Holdings by 8.6% in the second quarter. Cowen Group Inc. now owns 63,000 shares of the company’s stock valued at $234,000 after buying an additional 5,000 shares during the period. Schwab Charles Investment Management Inc. raised its stake in shares of Organovo Holdings by 1.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 264,596 shares of the company’s stock worth $985,000 after buying an additional 3,654 shares during the last quarter. A.R.T. Advisors LLC acquired a new stake in shares of Organovo Holdings during the second quarter worth about $231,000. Rhumbline Advisers raised its stake in shares of Organovo Holdings by 19.5% in the second quarter. Rhumbline Advisers now owns 99,758 shares of the company’s stock worth $371,000 after buying an additional 16,245 shares during the last quarter. Finally, Lehman Financial Resources Inc. raised its stake in shares of Organovo Holdings by 1.2% in the second quarter. Lehman Financial Resources Inc. now owns 131,400 shares of the company’s stock worth $488,000 after buying an additional 1,500 shares during the last quarter. Hedge funds and other institutional investors own 19.11% of the company’s stock.
Organovo Holdings Company Profile
Receive News & Stock Ratings for Organovo Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo Holdings Inc and related stocks with our FREE daily email newsletter.